These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 28162234)

  • 1. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
    Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
    Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of testing for germline
    Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
    Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.
    Pokharel HP; Hacker NF; Andrews L
    Aust N Z J Obstet Gynaecol; 2016 Dec; 56(6):633-638. PubMed ID: 27530527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
    Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
    Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
    George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
    Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
    Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
    BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integration of BRCA testing into oncology clinics.
    Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S
    Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing practice: moving to a specialist nurse-led service for BRCA gene testing.
    Scott N; O'Sullivan J; Asgeirsson K; Macmillan D; Wilson E
    Br J Nurs; 2020 May; 29(10):S6-S13. PubMed ID: 32463748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
    Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
    Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    McCuaig JM; Care M; Ferguson SE; Kim RH; Stockley TL; Metcalfe KA
    Gynecol Oncol; 2020 Sep; 158(3):747-753. PubMed ID: 32674931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
    Burling MJ; Gamet K; Eva L; Tan AL
    Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
    Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
    Rahman B; Lanceley A; Kristeleit RS; Ledermann JA; Lockley M; McCormack M; Mould T; Side L
    J Med Genet; 2019 Mar; 56(3):195-198. PubMed ID: 29535157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keeping it simple: genetics referrals for all invasive serous ovarian cancers.
    Demsky R; McCuaig J; Maganti M; Murphy KJ; Rosen B; Armel SR
    Gynecol Oncol; 2013 Aug; 130(2):329-33. PubMed ID: 23707676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.